Good Question, I too had same Thought

HI All,

Who are the listed competitors for Mold-tek?. Trying to find how the market share is divided… Does Mold-tek have leading market share in any segment?

Tried to find competitors
uflex,Polyplex – More on Films?
TCPL – Cartons
EPL – more on fmcg
rajshreepolypack; ArrowGreen – Seem too small
Hitech Corporation – Seems to be the one with similar areas and size.

Can you share your thoughts on whom I should look for similar size and whether any market share information is available.

Thanks in advance

Hi sir. I think wrt to debt the company said something different. Net Total Debt at 539cr. Will pay Rs 40cr this year as part of term loan instalment. Next year’s conservative payback target is Rs. 100cr (57-58 Cr regular instalment + pay extra).

Q3 FY24 Earnings Conference Call of Alembic Pharmaceuticals Limited February 05, 2024

• Specialty therapies performed better than the market. Gynecology, gastro, antidiabetic, and ophthalmology therapies outpaced the market growth

• We performed relatively better than the market in antibiotics and respiratory segments on a higher basis in the previous year’s Q3

• New launches continue to do well with promising future launches across key segments

• Animal Health had a fantastic quarter and this is a business that’s been doing very well for us. It grew by 32% during the quarter

INTERNATIONAL BUSINESS:

• We had a very satisfactory quarter with exceptional growth in the ex-US generics. The US business also grew 9% on the back of 11 launches. The US business is looking better right now with new facilities already commercialized. As they ramp up, we will get a lot of operating leverage, and cost improvements are also on track

• There is no further large CAPEX needed for the international business and we will have only maintenance CAPEX as well as some API expansion, including in therapies such as GLP-1 and debottlenecking

• The API business has been very strong for us over the last couple of years. The de-growth this quarter was due to lower offtake from a few select customers since it’s getting lumpy. I expect another quarter or two maybe weaker, and then we should be back to our regular growth rate that we demonstrated in the past

• R&D expense was at 7% of sales at Rs. 114 crores for the quarter.

• We filed 5 ANDAs during the quarter and cumulatively ended up filings at 257. We also received seven approvals and launched 11 products. We should launch about 5 products in the next quarter as well.

• The U.S. generics business grew 9% to Rs. 474 crores for the quarter. The ex-US grew by 32% to Rs. 272 crores, and the API business grew by 11% to Rs. 289 crores.

They have an edge as they started early and grown in a consistent manner. We have very less competitors in this segment and to grow to this level others will take time.

I have invested with great level of conviction.